2010 Scrip 100 - David Brennan juggling pharma and PhRMA
This article was originally published in Scrip
Executive Summary
It was never going to be a quiet year for David Brennan. A slowing pipeline, neutral ratings from analysts and a recession were among the challenges that AstraZeneca's CEO addressed in 2009. Now he's fighting the industry's corner as the US market braces itself for healthcare reform. He tells Christopher Spillane how pharma is getting reform on its own terms as the industry contracts.